Figure 7.

I.T. administration of nanovaccine shows higher distant antitumor efficacy. (A–C) C57BL/6 mice were inoculated with 1.5×10⁵ TC-1 cells on day 0 and 2×10⁴ TC-1 cells in the left flank on day 4. Mice were treated with I.T. or S.C. vaccination on days 10 and 17 and I.T. PBS was set as control (A). Tumor growth was monitored (n=5) (B, C). (D–F) C57BL/6 mice were subcutaneously inoculated with 1.5×10⁵ B16-OVA cells on day 0 and intravenously injected with 1×10⁵ B16-OVA cells on day 5. Mice received vaccination on days 6, 11 and 16 and I.T. PBS was set as control (n=5). (D) Growth curve of primary tumor (E) and the lung metastasis (F) were shown. ***P<0.001, **p<0.01, *p<0.05, One-way ANOVA t-test. ANOVA, analysis of variance; I.T., intratumoral; NS, not significant; S.C., subcutaneous.